Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
Financial updatesPharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent.
2025
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
Financial updatesOn December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the shareholders of Abliva AB (publ) (“Abliva”) to tender all their shares in Abliva to Pharming at a price of SEK 0.45 in cash per share (the “Offer”). An offer document relating to the Offer was published on January 15, 2025.
2024
Pharming announces public cash offer to the shareholders of Abliva AB
Financial updatesPharming Group N.V. today announced a recommended public cash offer to the shareholders of Abliva AB (“Abliva”) to acquire all issued and outstanding shares of Abliva.
Pharming Group reports third quarter 2024 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2024.
Pharming Group to report third quarter 2024 financial results on October 24
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.
Pharming Group reports second quarter and first half 2024 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2024.
Pharming Group to report second quarter and first half 2024 financial results on August 1
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
Financial updatesTHIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM THEIR STOCKBROKER, SOLICITOR, ACCOUNTANT OR OTHER INDEPENDENT FINANCIAL OR LEGAL ADVISER. THIS NOTICE IS NOT FOR DISTRIBUTION IN OR TO ANY PERSON LOCATED IN ANY JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Pharming Group reports first quarter 2024 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the three months ended March 31, 2024.
Pharming Group to report first quarter 2024 financial results on May 8
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024.